RecruitingRecruiting
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237 · Tonix Pharmaceuticals, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
About this study
The goal of this clinical trial is to learn if a drug called TNX-102 SL works to treat moderate to severe major depressive disorder in adults. It will also learn about the safety of TNX-102 SL. The main questions it aims to answer are:
Does TNX-102 SL improve depression symptoms according to a depression symptom rating scale? What medical problems do participants have when taking TNX-102 SL?
Researchers will compare TNX-102 SL to a placebo (a look-alike substance that contains no drug) to see if TNX-102 SL works to treat major depressive disorder.
Participants will:
Take TNX-102 SL or a placebo every night at bedtime for 6 weeks Visit the clinic once every 2 weeks for checkups and tests
Eligibility criteria
Inclusion Criteria:
* Primary DSM-5 diagnosis of current MDD.
* The duration of the current MDE must be between 6 weeks and 18 months.
* Without psychotic or catatonic features.
* Capable of reading and understanding English and able to provide written informed consent to participate.
Exclusion Criteria:
* Diagnosis of DSM-5-defined lifetime bipolar disorder (I, II, or unspecified), schizophrenia, schizoaffective disorder, MDD with psychotic features, other psychotic disorder, or antisocial personality disorder; current (past month) obsessive-compulsive disorder; current (past month) posttraumatic stress disorder; current (past 3 months) anorexia nervosa,
* Diagnosis of borderline personality disorder that is known, suspected
* Participants with comorbid generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder are excluded only if the GAD, SAD, or panic disorder is considered the primary psychiatric diagnosis, rather than MDD.
* Participants with treatment refractory MDD, ie, previously having failed in their lifetime ≥2 treatments (due to inadequate efficacy) with at least 2 different classes of antidepressants of adequate dose, duration, and treatment adherence.
* History of substance use disorder and/or alcohol use disorder during the preceding 12 months
* Use of antidepressants (including ketamine/esketamine, St. John's Wort, S-adenosyl methionine, and/or trazodone used as an antidepressant) within 4 weeks of Baseline (Visit 2), except for fluoxetine, which must not be within 6 weeks of Baseline (Visit 2)
Study design
Enrollment target: 360 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-06-25
Estimated completion: 2028-02
Last updated: 2026-10-30
Interventions
Drug: TNX-102 SLDrug: Placebo sublingual tablet
Primary outcomes
- • Change from Baseline (Visit 2) in the MADRS total score at Week 6. (From Day 1 to Week 6)
Sponsor
Tonix Pharmaceuticals, Inc. · industry
Contacts & investigators
ContactTimothy Roush · contact · timothy.roush@tonixpharma.com · (862) 799-8599
All locations (27)
Clinical Research SiteRecruiting
Phoenix, Arizona, United States
Clinical Research SiteRecruiting
Buena Park, California, United States
Clinical Research SiteRecruiting
Chino, California, United States
Clinical Research SiteRecruiting
Lemon Grove, California, United States
Clinical Research SiteRecruiting
Orange, California, United States
Clinical Research SiteRecruiting
San Diego, California, United States
Clinical Research SiteRecruiting
Walnut Creek, California, United States
Clinical Research SiteRecruiting
Jacksonville, Florida, United States
Clinical Research SiteRecruiting
Maitland, Florida, United States
Clinical Research SiteRecruiting
Miami, Florida, United States
Clinical Research SiteRecruiting
Orange City, Florida, United States
Clinical Research SiteRecruiting
Orlando, Florida, United States
Clinical Research SiteRecruiting
Tampa, Florida, United States
Clinical Research SiteRecruiting
Norcross, Georgia, United States
Clinical Research SiteRecruiting
Chicago, Illinois, United States
Clinical Research SiteWithdrawn
New Orleans, Louisiana, United States
Clinical Research SiteRecruiting
Rockville, Maryland, United States
Clinical Research SiteRecruiting
Methuen, Massachusetts, United States
Clinical Research SiteRecruiting
Las Vegas, Nevada, United States
Clinical Research SiteRecruiting
New York, New York, United States
Clinical Research SiteRecruiting
North Charleston, South Carolina, United States
Clinical Research SiteRecruiting
Mephis, Tennessee, United States
Clinical Research SiteRecruiting
Austin, Texas, United States
Clinical Research SiteRecruiting
Dallas, Texas, United States
Clinical Research SiteRecruiting
McKinney, Texas, United States
Clinical Research SiteRecruiting
Plano, Texas, United States
Clinical Research SiteRecruiting
Provo, Utah, United States